BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ARS Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ARS Pharmaceuticals\, Inc.'s drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06927999-8938@assetmemo.bio
DTSTAMP:20261121T010117Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:neffy (Epinephrine): Phase 2 readout est. (NCT06927999)
DESCRIPTION:neffy (Epinephrine)\, phase 2.\nStudy: An Outpatient Study of t
 he Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria\nEstim
 ated primary completion: June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/epinephrine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06927999
URL:https://assetmemo.bio/drug/epinephrine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
